Pharnext (FR:ALPHA) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Pharnext SCA, a biopharmaceutical company focused on neurodegenerative diseases, has initiated liquidation proceedings after failing to secure funding post-conciliation. The Paris Commercial Court has appointed a liquidator and trading of Pharnext’s shares has been suspended. Shareholders are unlikely to receive any payment from asset sales due to the company’s liabilities and are warned of potential capital loss and share dilution.
For further insights into FR:ALPHA stock, check out TipRanks’ Stock Analysis page.
